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ResouRCe use AssoCiAted with PAtieNts with thyRoid CANCeR iN A 
uNited stAtes iNsuRed PoPulAtioN
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Objectives: Thyroid cancer is a rare and heterogeneous disease. While many 
patients have a good prognosis, a subset of 5-20% experience recurrence and pro-
gressive disease. Resource use in patients with thyroid cancer, and specific subtypes 
such as medullary thyroid cancer (MTC) and differentiated thyroid cancer (DTC), are 
not well characteristised; therefore, the study evaluated characteristics, health care 
utilization and costs in a commercially insured US population. MethOds: A retro-
spective observational cohort analysis, using the HealthCore Integrated Research 
Environment (HIRE) for the period 01/1/2006 through 8/31/2012, was conducted. 
Cases were defined by at least 2 diagnoses of thyroid cancer within 60 days, and 
algorithms were developed to further sub-classify patients into histologic groups. 
Baseline (defined as 12 months prior to first diagnosis) and post-diagnosis charac-
teristics and costs were calculated. Results: 6,823 thyroid cancer patients were 
identified, including 280 MTC, 3,238 DTC. Mean age was 49.2 years and less than 
1% were children; 76% of patients were female. At baseline, the most common 
comorbidities were infection (45%), hypertension (33%), hypothyroidism (32%) and 
chronic fatigue (21%). Resource use and medication utilization was substantially 
different between subgroups. 63% of all patients had at least one post-diagnosis 
hospitalisation, which was higher in DTC (77%) and MTC (70%) than uncatego-
rised patients. Around 30% of all patients had ≥ 1 emergency department visit. 
DTC patients filled significantly more thyroid specific medications. Patients with 
advanced disease(N= 2,399) had more comorbidities, greater health care utilization 
and costs. Total health care costs per patients year across all patients was $17K, 
and were significantly higher in patients with MTC ( $24K), and those with any 
advanced thyroid cancer ($46K). cOnclusiOns: Thyroid cancer is a costly and 
resource intensive disease. While MTC patients incurred greater total health care 
costs, driven largely by hospitalizations and outpatient visits, advanced disease was 
associated with the highest resource utilization and costs.
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the RARe diseAse of mANtle Cell lymPhomA (mCl)
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Objectives: Assess the annual number of patients with MCL who relapse or are 
refractory to first line therapy in selected European countries. MethOds: A sys-
tematic literature review, aiming to identify and summarize all evidence related 
to outcomes of current treatment options for MCL was conducted. A comprehen-
sive literature search of two databases (PUBMED and Cochrane) from 2005-2014, 
and proceedings from major hematology/oncology conferences was undertaken. 
In addition, data from various cancer registries, surveillance and cohort studies 
were analyzed. Incidence and prevalence of MCL was calculated and patient out-
comes (e.g. overall response rate [ORR] and progression-free survival [PFS]) were 
summarized. Data analysis was stratified for subpopulations by age, ECOG per-
formance status and first-line treatment options available in the countries under 
study (Belgium, France, Germany, Italy, The Netherlands, Poland, Spain, Sweden and 
the UK). Results: The proportion of MCL as a subtype of NHL ranges from 2.0% to 
7.1%. Minimum and maximum estimates of the newly diagnosed total patients with 
MCL in Europe range from 3,219 to 6,177 patients (0.6 – 1.2 per 100,000) in 2012, and 
the estimated prevalence ranges from 9,014 to 17,296 (1.8 – 3.4 per 100,000). Overall 
response (OR) rates after first line immunochemotherapy in MCL patients ranges 
from 63% to 97%, complete response (CR) rates range from 15% to 96%. Progression-
free survival (PFS) ranges from 16 months to 83 months. Based on evidence derived 
from this review, the steady-state prevalence of patients with relapsed or refractory 
MCL ranges from 1,778 – 8,799 patients annually, requiring second line treatment in 
the countries under study. cOnclusiOns: Despite improved treatment alternatives 
and improved outcomes in patients with MCL, remission duration is still short and 
the proportion of patients needing 2nd line and subsequent lines of therapy is high.
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Objectives: To determine whether a new cancer diagnosis affects drug therapy for 
diabetes among Medicare beneficiaries. MethOds: We identified diabetes patients 
from a 5% random sample of Medicare beneficiaries enrolled in Medicare Part D in 
2007 and 2008. We then identified the subset with newly diagnosed cancer between 
January and December 2007 (N= 4,457). The comparison group represented ben-
eficiaries with diabetes who had no evidence of cancer during the study period 
(N= 29,187). Use and adherence with oral hypoglycemic agents, RAAS-inhibitors, and 
statins were tracked during 6-month periods prior to and after cancer diagnosis and 
a matching index date for non-cancer controls. Monthly adherence was measured 
by the percentage of days covered (PDC). We estimated difference-in-difference-in-
difference (DDD) equations to assess the independent impact of cancer diagnosis 
and poor prognosis (died in month 7 to 12 after index date) on PDC controlling for 
individual characteristics. Results: We found that adherence declined between 
the pre-index and post-index periods for all drug classes with the sharpest drop 
evident among cancer patients who subsequently died in month 7 to 12. Depending 
on drug class, a cancer diagnosis reduced PDC by 4.7% to 6.1% among survivors and 
by 7.6% to 16.4% for decedents. Among non-cancer controls, the declines ranged 
between 1.5% and 3.2% (survivors) and between 5.7% and 9.1% (decedents). Similarly, 
Objectives: Major discordance for the initial diagnosis could induce a strong 
impact on therapeutic strategies and costs. To deal with this problem, the cost of dis-
cordant diagnoses was assessed in sarcoma patients treated in France. MethOds: 
This multicenter analysis was performed retrospectively using prospective-imple-
mented databases. Inclusion criteria were sarcoma patients with a discordant 
diagnosis after histological review performed within the RRePS network in 2010. 
Diagnoses were considered discordant when the final diagnosis was not categorized 
in the same way as the initial finding, as defined by the World Health Organization 
Classification. Therapeutic strategies related to the diagnosis were based on patient 
and disease characteristics and using national or international guidelines when 
available. All the strategies were defined by the authors. Related costs were assessed 
for initial diagnosis inducing specific managements and the management expected 
with the restored diagnosis after second opinion by pathologist expert. Costs were 
assessed according to the French National Health Insurance (NHI) perspective. The 
time horizon included initial treatments and a one year follow-up period. All costs 
were expressed in Euros 2013. Uncertainty was assessed by probabilistic sensitivity 
analysis. Results: Out of the 2,425 patients that underwent histological review, 
341 patients had a major discordance in their diagnosis (14.1%). Ten patients were 
excluded due to missing data. The costs of the therapeutic strategies for the initial 
diagnosis reached € 2,186,816 for the NHI. More precisely, costs [95% CI] reached: 
€ 696,452 [€ 535,745–€ 857,159] for gastrointestinal stromal tumors (GIST) (n= 35) 
confounded with non-GIST; € 695,755 [€ 547,822–€ 843,688] for sarcoma (n= 74) con-
founded with non-sarcoma malignant tumors; € 533,987 [€ 450,333–€ 617,641] for sar-
coma confounded with benign tumors (n= 117). cOnclusiOns: This study revealed 
the high cost of the therapeutic strategies resulting from misdiagnosis. Based on 
the publication of Lapeyrere, where the cost per histological review reached € 228, 
histological reviews would result in a cost saving of € 1,633,916 in 2010.
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Objectives: Assess the annual number of patients with chronic lymphocytic leu-
kemia (CLL)/small cell lymphocytic leukemia (SLL) who relapse or are refractory to 
first line therapy in selected European countries. MethOds: A systematic litera-
ture review, aiming to identify and summarize all evidence related to outcomes of 
current treatment options for CLL/SLL was conducted. A comprehensive literature 
search of two databases (PUBMED and Cochrane) from 2005-2014, and proceed-
ings from major hematology/oncology conferences was undertaken. In addition, 
data from various cancer registries, surveillance and cohort studies were analyzed. 
Incidence and prevalence of CLL/SLL was calculated and patient outcomes (e.g. 
overall response rate [ORR] and progression-free survival [PFS]) were summarized. 
Data analysis was stratified for subpopulations by age, ECOG performance status, 
presence of del17p and first-line treatment options available in the countries under 
study (Belgium, France, Germany, Italy, The Netherlands, Poland, Spain, Sweden 
and the UK). Results: The incidence of CLL/SLL ranges from 4.9 to 6.9 per 100,000 
in the countries under study. The estimated number of newly diagnosed patients 
each year with CLL/SLL in Europe ranges from 19,383 to 26,411. ORR after first line 
chemo-immunotherapy ranged from 63% to 95%, with complete response rates 
ranging from 5% to 47%. PFS rates ranged from 19 to 80 months. Based on evidence 
derived from this review, the steady-state prevalence of patients with relapsed or 
refractory CLL/SLL resulted in 9,174 to 19,579 patients annually, requiring second 
line treatment in the countries under study. cOnclusiOns: CLL/SLL represents 
the largest adult leukemia in the western world. This systematic literature review 
identified the significant number of patients failing first-line therapy with relapsed 
or refractory disease. Despite the improved response rates achieved in the last dec-
ade, duration of response varies, with some patients having short durations only. 
Therefore, further improvement in treatment options is required.
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PsA moNitoRiNg ANd Results AmoNg meN with NoN-metAstAtiC 
PRostAte CANCeR
Wilson K.L., Foley K.A.
Truven Health Analytics, Bethesda, MD, USA
Objectives: Prostate-specific antigen (PSA) monitoring following a diagnosis of 
prostate cancer remains controversial. We sought to describe results and pre-
dictors of PSA monitoring among non-metastatic prostate cancer patients with 
employer sponsored health insurance. MethOds: Male patients with ≥ 2 medi-
cal claims with a diagnosis of prostate cancer (ICD-9-CM code 185.00) between 
1/1/2008-4/30/2013 (index date) were evaluated in Truven Health MarketScan 
Treatment Pathways 3.0. Included patients had ≥ 6 mo continuous enrollment 
prior to and ≥ 24 mo of continuous enrollment following their index date and 
no diagnosis of metastatic cancer anytime during the study period. Receipt of 
PSA laboratory tests following cancer diagnosis was evaluated in the follow-up 
period. Results: In total, 7,893 men met the inclusion criteria. 6,558 (83%) had 
a PSA test post-index and 69% of them had a second PSA. Mean days from index 
to first and second PSA were 372 and 220 days, respectively. Mean age was 59 
years among those with a PSA test and 72 years among those without. Of the 
2,245 patients with an available test result, 85% had normal PSA scores (77% 0 to 
< 2 ng/mL; 8% 2 to < 4 ng/mL), while 4.4% were ≥ 10 ng/mL. PSA was normal for 
89% (81% 0 to < 2 ng/mL; 8% 2 to < 4 ng/mL) with a 2nd PSA, while 3% were ≥ 10 
ng/mL. Men without a PSA test were more likely to have comorbid hypertension 
(74% vs. 20%), hyperlipidemia (60% vs. 20%), and diabetes (35% vs. 9%) than those 
with a test. cOnclusiOns: The majority of men had at least 1 PSA test within 
the first year following their diagnosis, and the majority of those results were in 
the normal range. Monitoring appears to be more common among healthier men. 
Future research should explore whether monitoring results in better outcomes.
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Objectives: To determine the publicly funded health care costs associated 
with breast cancer (BC) by stage of disease in the first two years following diag-
nosis. MethOds: Incident cases of female invasive BC (ICD-9 174.x) diagnosed 
between 2005 and 2009 were extracted from the provincial cancer registry and linked 
by their encrypted health card number to administrative datasets. The type and 
usage of publicly funded health care services used were stratified by disease stage 
over the first two years following diagnosis. BC cases were matched to controls 
(women without cancer). Overall average costs (2008$CAN) and costs per resource 
per BC case were compared to a control group. The attributable cost for the two-year 
time horizon was determined. Results: There were 39,655 BC cases and 190,520 
controls in our cohort study. The average age was 61.1 years old and 60.9 years old, 
respectively. Of the BC cases with staging information, the majority of cases were 
Stage I (34.4%) and Stage II (31.8%). Eight percent of the entire cohort died within 
the first two years of diagnosis. The overall mean cost per BC case from a public 
payer perspective in the first two years following diagnosis was $41,686 based on the 
study cohort of 39,655 BC cases. The mean cost increased by stage: Stage I ($29,938), 
Stage II ($46,893), Stage III ($65,369) and IV ($66,627). When compared to controls, 
the net cost for BC cases was $31,732. Cost drivers for the entire cohort were can-
cer clinic visits, physician billing and inpatient hospitalizations. cOnclusiOns: 
Costs increased by stage of disease. Cost drivers were identified and a net cost was 
calculcated. This data will allow for planning and decision making around limited 
health care resources.
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tReAtmeNt PAtteRNs AmoNg PAtieNts with bReAst CANCeR: does 
iNsuRANCe stAtus mAtteR?
Jiao X., Mu G., Cai Y.
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Objectives: Mixed results have been reported on the associations between insur-
ance coverage and cancer treatment, probably due to different population involved. 
This study was conducted to investigate treatment patterns by insurance status 
in patients with breast cancer using a large national database. MethOds: The 
National Cancer Database (NCDB) was used to examine the initial treatment after 
diagnosis. Patients were classified into the early stage group (stage 0-2) and the 
advanced stage group (stage 3-4). Logistic regressions were used to estimate the 
Odds ratios (ORs, with confidence intervals [95% CIs]) of receiving surgery, hor-
mone therapy, and chemotherapy by insurance status. Results: A total of 2,317,286 
patients with breast cancer were retrieved from the database during the study 
period (2000-2011). Patients with private insurance, Medicare, Medicaid or no insur-
ance accounted for 53.8%, 35.5%, 4.8%, and 2.2% respectively. Compared with the 
uninsured, patients with private insurance, Medicare, or Medicaid were more likely 
to receive surgery in both early stage group (OR 2.97, [2.83-3.11], OR 2.00, [1.90-2.09], 
OR 1.58, [1.49-1.67] respectively) and advanced stage group (OR 2.89, [2.78-3.01], OR 
1.45, [1.39-1.51], OR 1.60, [1.53-1.68] respectively). In the early stage group, patients 
with private insurance and Medicare were more likely to undergo partial mastec-
tomy than the uninsured (OR 1.40, [1.37-1.43], OR 1.36, [1.33-1.39]), while patients 
with Medicaid had similar utilization of partial mastectomy as the uninsured 
(OR 1.02, [1.0-1.05]). In the advanced stage group, patients with private insurance, 
Medicare, or Medicaid were more likely to receive hormone therapy (OR 1.54, [1.48-
1.60], OR 1.68, [1.61-1.74], OR 1.20, [1.15-1.26]) than the uninsured. Patients with 
private insurance and Medicaid were also more likely to receive chemotherapy (OR 
1.67, [1.60-1.74], OR 1.39, [1.32-1.46]), while patients with Medicare were less likely 
to receive chemotherapy (OR 0.36, [0.34- 0.37]) than the uninsured. cOnclusiOns: 
Insurance status is associated with different treatment patterns. It may have an 
impact on clinical management of patients with breast cancer.
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Objectives: The study aims to systematically review the efficacy, safety and 
cost-effectiveness of trastuzumab in metastatic gastric cancer treatment in 
China. MethOds: A systematic review method was performed. We collected both 
national and international clinical, cost-effectiveness and disease burden stud-
ies mainly from database of Pubmed, MEDLINE, CNKI, etc. And health insurance 
status of trastuzumab in China was also collected. Results: With inclusion and 
exclusion criteria, there were 8 clinical studies, 2 cost-effectiveness study and 19 
disease burden studies finally recruited for the analysis. Clinical results showed 
that trastuzumab in combination with chemotherapy were effective and well toler-
ated in target population. In ToGA, the only phase III randomized controlled trial, 
compared with chemotherapy alone, trastuzumab plus chemotherapy substantially 
improved overall survival (13.8 vs. 11.1 months) and progression-free survival (6.7 
vs. 5.5 months). One cost effectiveness study revealed that from the perspective of 
UK NHS, ICER of trastuzumab plus chemotherapy among IHC3+ or IHC2+/FISH+ 
patients was 66,982-71,637 pounds per QALY, compared with chemotherapy alone. 
Gastric cancer had brought a heavy disease burden to China. The DALY lost from 
gastric cancer was 1.48-5.03 per thousand patients and average hospitalization 
expenditure per patient was rising. By the first half year of 2013, there were more 
than 6 provinces and cities in China providing public reimbursement for trastu-
zumab, but only 2 for gastric cancer indication. cOnclusiOns: Trastuzumab with 
chemotherapy can be considered as a new standard option for HER2-positive meta-
static gastric cancer patients. However, more evidences on efficacy, safety and cost 
effectiveness of trastuzumab are still needed to support local public decision making 
on health insurance benefits update in China.
the DDD results indicated small declines in medication adherence for cancer sur-
vivors relative to beneficiaries without a cancer diagnosis in all three drug classes 
(3 to 5 percentage points), whereas longer term cancer survivors had much better 
adherence to all three drug classes (10 to 12 percentage points higher) relative to 
beneficiaries with cancer who had a poor prognosis. cOnclusiOns: A diagnosis of 
cancer among Medicare beneficiaries with diabetes significantly reduces adherence 
with evidence-based medications recommended in diabetes treatment guidelines.
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beNefiCiARies with ColoReCtAl CANCeR
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Objectives: To examine total health care-expenditures in the initial phase-of-care 
among Medicare beneficiaries with colorectal cancer (CRC) from a rural setting, 
and compare them with “national” estimates. MethOds: A population-based ret-
rospective cohort-study was conducted on fee-for-service Medicare beneficiaries 
aged ≥ 66 years diagnosed with CRC between 2003-2006 identified from the West 
Virginia Cancer Registry (WVCR)-Medicare linked database (n= 2,114). Similarly, a 
comparative cohort was identified from Surveillance, Epidemiology, and End Results 
(SEER)-Medicare (n= 38,172). Medicare claim payment-amounts were used to cal-
culate total average health care, inpatient, outpatient, physician-visits, and other 
health care-utilization expenditures. To control for geographic variation in cost-of-
living across the different counties, health care-expenditures were expressed using 
county-specific cost-of-living indices (COLI). Results: After COLI-adjustment, the 
average total health care expenditures in the initial phase-of-CRC care for those 
from the WVCR-Medicare linked-database were estimated at $46,644. The average 
total health care and inpatient expenditures in initial phase-of-care were found to 
be lower (5% and 4%, respectively) for those from WVCR-Medicare as compared to 
those from SEER-Medicare. However, they had a higher co-morbidity burden, and 
significantly higher (45%) outpatient expenditures as compared to their “national” 
counterparts. The outpatient expenditures were higher specifically for beneficiaries 
with chronic-conditions, which have a higher prevalence in the WVCR-Medicare 
group as compared to those from SEER-Medicare. Further, the differences in total 
health care-expenditures between beneficiaries from WVCR-Medicare and SEER-
Medicare reduced from $2,282 to $898, and remained no longer significant in a 
multivariable setting after controlling for receipt of minimally-appropriate CRC 
treatment (MACT) and presence of chronic-conditions. cOnclusiOns: This study 
highlights the importance of providing preventive health care services and better 
co-management of CRC and chronic-conditions, to control the higher outpatient 
expenditures among beneficiaries with CRC from a rural population. This study 
also showed that the differences in total health care-expenditures between rural 
and “national” population are likely to be partially explained by the receipt of MACT 
and comorbidity-burden.
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Objectives: To examine colorectal cancer (CRC) treatment patterns in the ini-
tial phase-of-care, the extent of receipt of minimally-appropriate CRC-treatment 
(MACT), the associated survival in a three-year period following a CRC-diagnosis 
in Medicare beneficiaries diagnosed with CRC from a rural setting, and to com-
pare these findings with “national” estimates. MethOds: A population-based 
retrospective cohort-study was conducted with data from fee-for-service Medicare 
beneficiaries aged ≥ 66 years diagnosed with CRC between 2003-2006 identified from 
the West Virginia Cancer Registry (WVCR)-Medicare linked database (n= 2,119). A 
comparative “national” cohort was identified from Surveillance, Epidemiology, and 
End Results (SEER)-Medicare (n= 38,168). CRC-treatment received was ascertained 
from beneficiaries’ Medicare claims by following them for 12-months from their 
CRC-diagnosis date or until death. Receipt of MACT was defined based on National 
Cancer Institute CRC-treatment guidelines. All-cause and CRC-specific mortality 
in the 36-month period following CRC-diagnosis were examined after accounting 
for selection bias using inverse probability treatment weights. Results: Although 
a higher proportion of beneficiaries from WVCR-Medicare were diagnosed in the 
earlier stages of CRC (when it can still be treated effectively) as compared to their 
SEER-Medicare counterparts, they had poorer CRC-survivorship with adjusted haz-
ards ratio (AHR)= 1.26;95%CI= [1.20,1.32]. This poorer survivorship may be due to 
a lower-likelihood (adjusted odds ratios (AOR)= 0.85;95%CI= [0.76,0.96]) of benefi-
ciaries from WVCR-Medicare of receiving MACT as compared to their “national” 
counterparts. Differences in usage of CRC-surgery, chemotherapy and radiation 
were also observed in the two populations. Those from WVCR-Medicare were less 
likely to receive any type of CRC-surgery with AOR= 0.82;95%CI= [0.73,0.93]. cOnc
lusiOns: This study highlights the need for an increased emphasis on adoption 
and adherence to accepted surgical and adjuvant CRC-treatment guidelines, and 
improving access to CRC-care for those from rural-settings. Further research needs 
to be conducted to determine if similar rural-urban differences in receipt of MACT 
exist in the elderly in other rural-areas of the nation.
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